SCHEMBL11943748

SCHEMBL11943748

O=c1c(-c2ccc(OC(F)(F)F)cc2)c(N2CCN(S(=O)(=O)Cc3ccccc3)CC2)cnn1-c1cc(F)cc(F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LIPE Q05469 1/20 0.44
▸ MAPT P10636 2/20 0.42
▸ HSD11B1 P28845 1/20 0.39
▸ ALDH1A1 P00352 4/20 0.37
▸ DCTPP1 Q9H773 1/20 0.37
▸ GLA P06280 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ PPARG P37231 1/20 0.37
▸ NCOA2 Q15596 1/20 0.37
▸ NCOA1 Q15788 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ NCOA3 Q9Y6Q9 1/20 0.37
▸ EGLN1 Q9GZT9 1/20 0.37
▸ MAPK1 P28482 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ GBA1 P04062 1/20 0.35
▸ GRM2 Q14416 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943641 0.90 MAPT (0.46) MAPTALDH1A1DCTPP1GLASMN1; SMN2
SCHEMBL11943746 0.90 MAPT (0.48) MAPTHSD11B1ALDH1A1DCTPP1POLB
SCHEMBL11943720 0.90 MAPT (0.48) MAPTHSD11B1ALDH1A1DCTPP1GLA
SCHEMBL11943638 0.90 MAPT (0.49) MAPTHSD11B1ALDH1A1DCTPP1POLB
SCHEMBL11943658 0.89 MAPT (0.44) MAPTHSD11B1ALDH1A1DCTPP1POLB
SCHEMBL11943665 0.89 MAPT (0.47) MAPTHSD11B1ALDH1A1DCTPP1GLA
SCHEMBL11943656 0.88 MAPT (0.49) MAPTHSD11B1ALDH1A1DCTPP1POLB
SCHEMBL11943708 0.88 MAPT (0.49) MAPTHSD11B1ALDH1A1DCTPP1POLB
SCHEMBL11943730 0.88 MAPT (0.46) MAPTHSD11B1ALDH1A1DCTPP1POLB
SCHEMBL11943559 0.88 MAPT (0.48) MAPTHSD11B1ALDH1A1DCTPP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA LIPE 3211/4885MAPT 2295/4885HSD11B1 1714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback